PHENYTOIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Phenytoin Sodium, and what generic alternatives are available?
Phenytoin Sodium is a drug marketed by Aurobindo Pharma, Pharmeral, Watson Labs, Acella, Am Regent, Fresenius Kabi Usa, Hospira, Marsam Pharms Llc, Smith And Nephew, Solopak, Warner Chilcott, and West-ward Pharms Int. and is included in sixteen NDAs.
The generic ingredient in PHENYTOIN SODIUM is phenytoin sodium. There are twenty-one drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the phenytoin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Phenytoin Sodium
A generic version of PHENYTOIN SODIUM was approved as phenytoin sodium by WEST-WARD PHARMS INT on December 31st, 1969.
Summary for PHENYTOIN SODIUM
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 16 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 248 |
Clinical Trials: | 19 |
Patent Applications: | 3,509 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PHENYTOIN SODIUM at DailyMed |
Recent Clinical Trials for PHENYTOIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hospital Israelita Albert Einstein | Phase 4 |
Industria FarmacĂȘutica Health Meds | Phase 4 |
Cambridge University Hospitals NHS Foundation Trust | Phase 3 |